STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Intellia Therapeutics announced that a single dose of lonvo‑z reduced hereditary angioedema attacks by 87% in an 80‑patient Phase 3 trial.
- lonvo‑z left more than 60% of treated patients attack‑free, compared with 11% in the placebo group.
- FDA is reviewing a rolling submission for lonvo‑z, which would become the first in‑vivo CRISPR therapy if approved.
Why it matters: Patients with hereditary angioedema gain an 87% attack reduction, while Intellia secures a new commercial product, driving a surge in CRISPR investment and lowering treatment costs.
